Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis

Int J Clin Pract. Jul-Aug 1998;52(5):289-97.

Abstract

The efficacy and safety of a five-day course of cefuroxime axetil (250 mg b.d.) and a seven-day course of clarithromycin (250 mg b.d.) were compared in a large double-blind, randomised, multinational study involving 684 patients with acute exacerbations of chronic bronchitis. In an intent-to-treat analysis, the post-treatment clinical responses to each treatment were comparable (82%) and rates at follow-up were similar: 64% on cefuroxime axetil and 61% on clarithromycin. Pre-treatment pathogens were isolated from a total of 192 patients, Haemophilus influenzae being the most common. Overall pathogen eradication rates were similar for both treatments. Both treatments were well tolerated. In conclusion, a five-day course of cefuroxime axetil is clinically equivalent to a seven-day course of clarithromycin in the treatment of acute exacerbations of chronic bronchitis, and may have potential socioeconomic benefits.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Bronchitis / drug therapy*
  • Cefuroxime / administration & dosage*
  • Cephalosporins / administration & dosage*
  • Chronic Disease
  • Clarithromycin / administration & dosage
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Clarithromycin
  • Cefuroxime